EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?

Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098206 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marina Popović und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the great progress made in the understanding of the biological behavior of certain types of invasive breast cancer, there is still no single histological or molecular classification that encompasses such diversity and accurately predicts the clinical course of distinct breast cancer subtypes. The long-lasting classification of breast cancer as HER2-positive vs. HER2-negative has recently come into question with the discovery of new antibody drug conjugates (ADC), which are proven to be remarkably efficient in treating HER2-low breast cancer. The HER2-low paradigm has challenged the traditional understanding of HER2 overexpression and emphasized the need for more robust HER2 testing in order to encompass HER2 intratumoral heterogeneity and spatial distribution more accurately. It is yet to be seen if low HER2 will remain merely a marker of HER2-equipped tumors targetable with ADCs or if distinctive molecular and phenotypic groups within HER2-low tumors will eventually be discerned.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsImmunoconjugatesHumansFemaleTrastuzumabAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesCamptothecin

Stichwörter der Autor:innen

HER2 amplificationHER2 heterogeneityHER2 lowHER2 overexpressionHER2 testingHER2-enrichedT-DXdantibody drug conjugatetrastuzumab deruxtecan

Substanzen

TrastuzumabAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsImmunoconjugatesCamptothecin

Autor:innen und Institutionen

  • Department of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

ORCID-Profile: Natalija Dedić Plavetić

Zitieren

APA

Popović, M., Silovski, T., Križić, M., & Dedić Plavetić, N. (2023). HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098206

Vancouver

Popović M, Silovski T, Križić M, Dedić Plavetić N. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098206

BibTeX
@article{Popovi2023,
  author = {Popović, Marina and Silovski, Tajana and Križić, Marija and Dedić Plavetić, Natalija},
  title = {HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098206}
}
Kostenlos starten →